Ann: Quarterly Activities Report and Appendix 4C, page-10

I wonder how important these new leads will prove to be!??

Hopefully, important discussions will be going on behind the scenes. This is the only feedback we have heard from management since attending the conference!

"In June 2024, executives from the Company attended the BIO International Convention in San Diego, CA."

"The Company conducted a broad range of meetings and discussions over the course of the conference and generated important new leads for a potential future partnership involving ATL1102. In addition, Percheron CEO, Dr James Garner, delivered a company presentation at the conference, which was well-attended.

(This should prove beneficial in the long term)
Percheron was also grateful to sponsor the 30th Annual Meeting of Parent Project Muscular Dystrophy (PPMD), one of the key patient advocacy groups in the United States for families affected by DMD. The meeting was held in Orlando, FL.
Percheron's Chief Medical Advisor, Dr Cathryn Clary, attended on behalf of the company and held meetings with clinicians and patient advocates.
Dr Clary also conducted an Advisory Board with several physicians who specialise in the treatment of DMD, and this provided very valuable insights into the evolving treatment paradigm, emerging novel therapies, and any future studies of ATL1102 that may be conducted in the United States."

I can't see the SP moving much until we get some substantial news!

GLTAH
.